Surgery results in greater improvement in weight loss outcomes and weight associated comorbidities compared with non-surgical interventions , regardless of the type of procedures used .
When compared with each other , certain procedures result ed in greater weight loss and improvements in comorbidities than others .
Outcomes were similar between RYGB and sleeve gastrectomy , and both of these procedures had better outcomes than adjustable gastric b and ing .
For people with very high BMI , biliopancreatic diversion with duodenal switch result ed in greater weight loss than RYGB .
Isolated sleeve gastrectomy led to better weight-loss outcomes than adjustable gastric b and ing after three years follow-up .
BACKGROUND Bariatric ( weight loss ) surgery for obesity is considered when other treatments have failed .
The effects of the available bariatric procedures compared with medical management and with each other are uncertain .
This is an up date of a Cochrane review first published in 2003 and most recently up date d in 2009 .
OBJECTIVES To assess the effects of bariatric surgery for overweight and obesity , including the control of comorbidities .
Is Laparoscopic Duodenojejunal Bypass with Sleeve an Effective Alternative to Roux En Y Gastric Bypass in Morbidly Obese Patients: Preliminary Results of a Randomized Trial
Background The incidence of obesity and related metabolic disorders in India and that of stomach carcinoma is one of the highest in the world . Hence , one requires a procedure that allows postoperative surveillance of the stomach with the best outcomes in terms of weight control and resolution of co-morbidities . Here , we compare one such procedure , duodenojejunal bypass with sleeve against the st and ard Roux-en Y gastric bypass . Methods Fifty-seven patients who were selected for a bypass procedure were r and omized into two groups of laparoscopic duodenojejunal bypass with sleeve ( DJB ) and laparoscopic Roux en Y gastric bypass . The limb lengths were similar in both the groups , and the sleeve was done over a 36F bougie . Results The mean body mass index and percent excess weight loss at the end of 3 , 6 , and 12 months between the groups were not statistically significant . The operating times were higher in the DJB group . The rate of resolution of diabetes , hypertension , and dyslipidemias were also similar with no statistical significance . There was 100 % resolution of dyslipidemias in both groups . There was one patient in the DJB group who presented with internal herniation 1 month post-op and was managed surgically . There was no mortality in both the groups . Conclusion Laparoscopic duodenojejunal with sleeve gastrectomy , a procedure which combines the principles and advantages of sleeve gastrectomy and foregut hypothesis , is a safe and effective alternative to gastric bypass in weight reduction and resolution of co-morbidities especially for Asian countries . But , long-term follow-up is required
Surgery results in greater improvement in weight loss outcomes and weight associated comorbidities compared with non-surgical interventions , regardless of the type of procedures used .
When compared with each other , certain procedures result ed in greater weight loss and improvements in comorbidities than others .
Outcomes were similar between RYGB and sleeve gastrectomy , and both of these procedures had better outcomes than adjustable gastric b and ing .
For people with very high BMI , biliopancreatic diversion with duodenal switch result ed in greater weight loss than RYGB .
Isolated sleeve gastrectomy led to better weight-loss outcomes than adjustable gastric b and ing after three years follow-up .
BACKGROUND Bariatric ( weight loss ) surgery for obesity is considered when other treatments have failed .
The effects of the available bariatric procedures compared with medical management and with each other are uncertain .
This is an up date of a Cochrane review first published in 2003 and most recently up date d in 2009 .
OBJECTIVES To assess the effects of bariatric surgery for overweight and obesity , including the control of comorbidities .